ClinicalTrials.gg
RecruitingNCT06966427DGSUpdated May 11, 2025

Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Injections

An interventional study of Dosing Guidance System to be used with both time and amount of insulin as input and Dosing Guidance System to be used with only time of insulin as input in Type 1 Diabetes and Type 2 Diabetes, sponsored by Rabin Medical Center. Recruiting at 2 sites in 2 countries. Open to participants aged 6 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by Rabin Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
6 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center — 8 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Rabin Medical Center.

Planned enrollment
14th of 38
45 · median 30
Started
2025
with 1 other
No phase
31 of 42
5 open now
Registered
41st of 42
by date

Among the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center, this one is the 14th largest by planned enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2025, is one of 31 with no phase, and was the 41st registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

8 of the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 6 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center, or all of them as a file.
02

Study summary

A prospective, randomized, single blind, two-arms, multicenter study. The study aims to assess the safety of a dosing-guided system (DGS) that provides direct advice on insulin dosing recommendations and diabetes management to individuals with diabetes using insulin or starting basal insulin therapy, guided by their continuous glucose monitoring (CGM).

The study population will include up to 45 individuals with diabetes, distributed as follows: 15 with Type 1 diabetes (T1D) and 15 with Type 2 diabetes (T2D), both on MDI therapy and 15 with T2D using or starting to use basal insulin.

The study will include a 2- to 4-week run-in period followed by a 6-week intervention period.

03

Conditions studied

  • Type 1 Diabetes
  • Type 2 Diabetes

Keywords

  • Type 1 diabetes
  • Type 2 diabetes
  • Dose guidance system
04

Who can participate

Ages eligible
6 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented T1D or T2D, for at least 6 months
  • Aged ≥ 6 years ≤ 75 years
  • ≤ 11%
  • For Segment 1: Using basal-bolus MDI therapy, i.e. basal insulin and a bolus that is either:

    1. Carbohydrate counting with carbohydrate ratio (CR) and correction factor (CF)
    2. Fix dose for meal / meal estimation with CF
  • For Segment 2: Using or prescribed basal insulin
  • Participants using the following type of insulin as directed in the instructions for use:

    1. Basal insulin: Glargine (including Rezvoglar, Semglee, Toujeo, Soliqua), Degludec (including Tresiba U-100, Tresiba U-200, Xultophy), Determir
    2. Bolus insulin: regular insulin, rapid analogues (Insulin Aspart, Insulin Glulisine, Insulin Lispro) or ultra-rapid analogues (Fiasp, Lyumjev)
  • Participants willing to use FreesStyle Libre CGM according to manufacturer instructions, document insulin delivery, meals, and daily activities.
  • Participants have a smartphone compatible with study requirements.
  • Participants are willing and able to sign a written form to use their data.
  • Participants are willing to use the bolus calculator for insulin dosing (only for segment 1)

Exclusion criteria

Exclusion Criteria:

  1. Concomitant diseases/treatment that influence metabolic control or any significant diseases/conditions including psychiatric disorders and substance abuse or drug or alcohol abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise patients' safety.
  2. Relevant severe organ disorders (diabetic nephropathy, diabetic retinopathy, diabetic foot syndrome) or any secondary disease or complication of diabetes mellitus, such as:

    1. Subject has unstable or rapidly progressive renal disease or has \< 45 or is receiving dialysis
    2. Subject has active proliferative retinopathy
    3. Active gastroparesis
  3. Participation in any other interventional study
  4. Female participant who is pregnant or planning to become pregnant within the planned study duration
  5. Individuals who are using one of the following types of insulin:

    1. Intermediate-acting insulin (NPH)
    2. Mixed insulin like:

    i. Premix NPH/ Regular (e.g. Humalin 70/30, Novolog 70/30) ii. Premix analogs (e.g, Novolog mix 70/30, Hu,alog mix 75, 25, Humalog Mix 50/50) c. Inhale insulin (e.g. Afrezza)

  6. Hypoglycemia unawareness
  7. Individuals who are treated with intravenous (IV) insulin injections, or a combination of insulin injections and/or IV insulin and insulin pump therapy.
  8. Individuals who have extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements.
  9. An episode of diabetic keto-acidosis within the month prior to study entry and/or severe hypoglycemia resulting in seizure or loss of consciousness in the month prior to enrolment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Dosing Guidance System- Group A

    Any insulin dosing event manually logged by the participant, the DGS will receive the time and amount of the dose as input.

    Device: Dosing Guidance System to be used with both time and amount of insulin as input

  • Experimental
    Dosing Guidance System-Group B

    Any insulin dosing event manually logged by the participant, the DGS will receive only the time of the dose as input

    Device: Dosing Guidance System to be used with only time of insulin as input

Interventions

  • DeviceDosing Guidance System to be used with both time and amount of insulin as input

    Any insulin dosing event manually logged by the participant, the DGS will receive the time and amount of the dose as input

    Also known as: endo.digital (Modi algorithm)

  • DeviceDosing Guidance System to be used with only time of insulin as input

    any insulin dosing event manually logged by the participant, the DGS will receive only the time of the dose as input

    Also known as: endo.digital (Modi algorithm)

06

What researchers measure

Primary outcomes

  1. Sensor glucose percentage of time in hypoglycemia below 54 mg/dL

    Will be compared between the last two weeks of the run-in period and the last two weeks of the intervention

    Time frame: Aafter 6 weeks of intervention period

Secondary outcomes

  1. Number of events of glucose readings below 54 mg/dL

    An event is defined as a period of at least 15 minutes of glucose readings below 54 mg/dL. Will be compared between the last two weeks of the run-in period and the last two weeks of the intervention

    Time frame: After 6 weeks of intervention period

  2. Sensor glucose percentage of time in hyperglycemia above 250 mg/dL

    Will be compared between the last two weeks of the run-in period and the last two weeks of the intervention

    Time frame: After 6 weeks of intervention period

Other outcomes

  1. Glucose Management Indicator (GMI)

    Time frame: After 6 weeks of intervention period

  2. Percentage of glucose readings between 70- 180 mg/dl

    Will be compared between the last two weeks of the run-in period and the last two weeks of the intervention

    Time frame: After 6 weeks of intervention period

  3. Change in (Hemoglobin A1c) HbA1C post-study treatment

    Time frame: After 6 weeks of intervention period

  4. Percentage of glucose readings below 70 mg/dl

    Will be compared between the last two weeks of the run-in period and the last two weeks of the intervention

    Time frame: After 6 weeks of intervention period

  5. Mean sensor glucose

    Will be compared between the last two weeks of the run-in period and the last two weeks of the intervention

    Time frame: After 6 weeks of intervention period

  6. Glucose variability measured by Standard Deviation (SD) and CV%

    Will be compared between the last two weeks of the run-in period and the last two weeks of the intervention

    Time frame: After 6 weeks of intervention period

  7. Time to reach optimal insulin dose

    Time frame: After 6 weeks of intervention period

  8. Total insulin dose and the amount of basal and/or bolus insulin dose

    Time frame: After 6 weeks of intervention period

  9. Device satisfaction questioner

    Time frame: After 6 weeks of intervention period

07

Study locations

1 of 2 sites recruiting
  • Schneider Children Medical Center of Israel
    Petach Tikva, 49202, Israel
    Not yet recruiting
    • Moshe Phillip, Prof · Contactmosheph@clalit.org.il · 972-3-9253282
    • Revital Nimri, MD · Sub investigator
  • University Medical Center of Ljubljana
    Ljubljana, Slovenia
    Recruiting
    • Andrej Janež, Prof · Contactandrej.janez@kclj.si · 0038615223564
    • Andrej Janež, MD, PHD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for May 2026, 12 months later.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 12 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 11, 2025
StartEst.
May 8, 2025
Primary completionEst.
May 25, 2026
CompletionEst.
May 25, 2026
Last update
May 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06966427
Collaborators
DreaMed Diabetes
Responsible party
Sponsor
First posted
May 11, 2025
Start date
May 8, 2025 (estimated)
Primary completion
May 25, 2026 (estimated)
Completion
May 25, 2026 (estimated)
Last update
May 11, 2025

Study contacts

Alona Hamou, Msc
Contact
alonah@clalit.org.il
972-545950277
Moshe Phillip, MD
principal investigator · Schneider Children's Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion